Izindaba Ezinhle:

I-Bioantibody iqede umjikelezo wayo wokuqala wokuxhasa ngezimali isamba esicishe sibe izigidi eziyi-100 zamayuan.Lezi zimali beziholwa ngokuhlanganyela yiFang Fund, New Industry Investment, Guoqian Venture Investment, bondshine capital kanye nePhoeixe Tree Investment.
Izimali zizosetshenziselwa ukusheshisa ukwakheka okujulile kwe-Bioantibody ekungeniseni izinkundla ezizenzakalelayo ezizenzakalelayo nezihlanganisiwe kanye nezinkundla zokwenza ngokwezifiso ze-OEM/ODM zamasosha omzimba, Imikhiqizo ye-#IVD, kanye nesevisi yezobuchwepheshe ehlobene njll.

I-Bioantibody igxile ku-R&D, ukukhiqizwa nokudayiswa kwezinto ezisetshenziswayo ezibalulekile ze-IVD kanye ne-biopharmaceuticals.Ngokusekelwe kubuchwepheshe bokuqala obuhlosiwe bokuhlanganiswa kwamaseli e-hybridoma kanye nezinto ezisekelayo zokukhula kwamaseli okuzinzile kanye nenkundla yokuhlola umkhiqizo ophezulu, inkampani ithuthukise imikhiqizo eminingana esebenza ngokuqhathaniswa noma edlula lokho kwempahla eluhlaza ye-IVD yezinga lokuqala emhlabeni. , kanye nokuhweba ngempumelelo.Kuye kwaqashelwa kakhulu futhi kwathengwa ngokuphindaphindiwe ngamakhasimende ezinkampani eziningi ezaziwa kakhulu ezisohlwini lwe-IVD e-China.

I-Bioantibody selokhu yasungulwa ihlala ithembekile esifisweni sayo sasekuqaleni, iphishekela ukuqamba okusha okuqhubekayo kanye nezinsizakalo zokunakekelwa kwezempilo ezinikezwe amandla ngobuchwepheshe.

Siyakuhalalisela!!